Pancreatic Cancer Research

ResearcherErasmus MCNo recent work listed

V.E.P.P. Lemmens

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4109-5734; OpenAlex author ID A5045771785, A5110182190. Sources: OpenAlex.

Their work

Papers
28 (first author 3, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
54
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: none · 2014: 1 paper · 2015: 4 papers · 2016: 6 papers · 2017: 4 papers · 2018: 5 papers · 2019: 3 papers · 2020: 1 paper · 2021: 2 papers

Papers 28

  1. Incidence, Treatment, and Survival of Synchronous Peritoneal Metastases in Pancreatic Cancer: Update of a Nationwide Cohort. Co-author DOI 10.1097/mpa.0000000000001857↗
  2. Significance of Examined Lymph Node Number in Accurate Staging and Long-term Survival in Resected Stage I-II Pancreatic Cancer-More is Better? A Large Internat… Co-author DOI 10.1097/sla.0000000000003558↗
  3. Conditional Survival After Resection for Pancreatic Cancer: A Population-Based Study and Prediction Model. Co-author DOI 10.1245/s10434-020-08235-w↗
  4. Association between primary origin (head, body and tail) of metastasised pancreatic ductal adenocarcinoma and oncologic outcome: A population-based analysis. Co-author DOI 10.1016/j.ejca.2018.10.008↗
  5. Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations. Co-author DOI 10.1136/gutjnl-2017-314828↗
  6. Development and validation of a prognostic model to predict the prognosis of patients who underwent chemotherapy and resection of pancreatic adenocarcinoma: a … Co-author DOI 10.1186/s12916-019-1304-y↗
  7. Trends in treatment and survival of patients with nonresected, nonmetastatic pancreatic cancer: A population-based study. Co-author DOI 10.1002/cam4.1750↗
  8. Nonsurgical therapies for resected and unresected pancreatic cancer in Europe and USA in 2003-2014: a large international population-based study. Co-author DOI 10.1002/ijc.31628↗
  9. Patient characteristics and treatment considerations in pancreatic cancer: a population based study in the Netherlands. Co-author DOI 10.1080/0284186x.2018.1470330↗
  10. Association of the location of pancreatic ductal adenocarcinoma (head, body, tail) with tumor stage, treatment, and survival: a population-based analysis. Co-author DOI 10.1080/0284186x.2018.1518593↗
  11. Stratified survival of resected and overall pancreatic cancer patients in Europe and the USA in the early twenty-first century: a large, international populati… Co-author DOI 10.1186/s12916-018-1120-9↗
  12. Nationwide outcomes in patients undergoing surgical exploration without resection for pancreatic cancer. First author DOI 10.1002/bjs.10602↗
  13. Nationwide trends in chemotherapy use and survival of elderly patients with metastatic pancreatic cancer. Co-author DOI 10.1002/cam4.1240↗
  14. Underestimation of pancreatic cancer in the national cancer registry - Reconsidering the incidence and survival rates. Co-author DOI 10.1016/j.ejca.2016.11.026↗
  15. Socio-economic status influences the likelihood of undergoing surgical treatment for pancreatic cancer in the Netherlands. First author DOI 10.1016/j.hpb.2017.01.010↗
  16. The use of adjuvant chemotherapy for pancreatic cancer varies widely between hospitals: a nationwide population-based analysis. Co-author DOI 10.1002/cam4.921↗
  17. Volume matters in the systemic treatment of metastatic pancreatic cancer: a population-based study in the Netherlands. Co-author DOI 10.1007/s00432-016-2140-5↗
  18. Common variables in European pancreatic cancer registries: The introduction of the EURECCA pancreatic cancer project. Co-author DOI 10.1016/j.ejso.2016.03.011↗
  19. Elderly Patients Strongly Benefit from Centralization of Pancreatic Cancer Surgery: A Population-Based Study. Last author DOI 10.1245/s10434-016-5089-3↗
  20. Does long-term survival exist in pancreatic adenocarcinoma? Co-author DOI 10.3109/0284186x.2015.1096020↗
  21. Pancreatic cancer surgery in elderly patients: Balancing between short-term harm and long-term benefit. A population-based study in the Netherlands. Last author DOI 10.3109/0284186x.2015.1105381↗
  22. Hospital of diagnosis and likelihood of surgical treatment for pancreatic cancer. Co-author DOI 10.1002/bjs.9951↗
  23. The relevance of pathological verification in suspected pancreatic cancer. Last author DOI 10.1016/j.canep.2015.01.004↗
  24. Survival in patients with primary liver cancer, gallbladder and extrahepatic biliary tract cancer and pancreatic cancer in Europe 1999-2007: Results of EUROCAR… Co-author DOI 10.1016/j.ejca.2015.07.034↗
  25. Ten weeks to live: a population-based study on treatment and survival of patients with metastatic pancreatic cancer in the south of the Netherlands. Last author DOI 10.3109/0284186x.2014.953257↗
  26. Impact of centralization of pancreatic cancer surgery on resection rates and survival. First author DOI 10.1002/bjs.9468↗
  27. Nationwide improvement of only short-term survival after resection for pancreatic cancer in the Netherlands. Last author DOI 10.1097/mpa.0b013e31824c3dbf↗
  28. Improving outcome for patients with pancreatic cancer through centralization. Co-author DOI 10.1002/bjs.7581↗

Closest collaborators

The 25 strongest of 54 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Lydia G. van der Geest · 17 shared papers, 2016–2021 · strength 1.39
  2. Marc G. Besselink · 17 shared papers, 2014–2021 · strength 1.31
  3. Ignace H. J. T. de Hingh · 15 shared papers, 2011–2021 · strength 1.00
  4. Hanneke W.M. van Laarhoven · 8 shared papers, 2015–2020 · strength 0.61
  5. Johanna W. Wilmink · 6 shared papers, 2016–2020 · strength 0.48
  6. Casper H.J. van Eijck · 6 shared papers, 2016–2020 · strength 0.45
  7. Lina Jansen · 5 shared papers, 2018–2021 · strength 0.40
  8. Lei Huang · 5 shared papers, 2018–2021 · strength 0.40
  9. Hermann Brenner · 5 shared papers, 2018–2021 · strength 0.40
  10. Bas Groot Koerkamp · 4 shared papers, 2018–2021 · strength 0.37
  11. Felice N. van Erning · 3 shared papers, 2018–2021 · strength 0.31
  12. Nadia Haj Mohammad · 4 shared papers, 2015–2019 · strength 0.29
  13. Robert Grützmann · 3 shared papers, 2019–2021 · strength 0.26
  14. Bert A. Bonsing · 4 shared papers, 2014–2020 · strength 0.25
  15. Izaak Quintus Molenaar · 4 shared papers, 2014–2020 · strength 0.24
  16. Geert‐Jan Creemers · 4 shared papers, 2015–2016 · strength 0.24
  17. Nienke Bernards · 4 shared papers, 2015–2016 · strength 0.24
  18. Maikel J. A. M. Bakens · 3 shared papers, 2015–2017 · strength 0.23
  19. Judith de Vos‐Geelen · 2 shared papers, 2018–2021 · strength 0.21
  20. Hjalmar C. van Santvoort · 2 shared papers, 2018–2021 · strength 0.20
  21. Tara M. Mackay · 2 shared papers, 2018–2019 · strength 0.17
  22. Myrte Zijlstra · 2 shared papers, 2016–2018 · strength 0.16
  23. Anouk Rijken · 1 shared paper, 2021 · strength 0.14
  24. Cornelis H.C. Dejong · 2 shared papers, 2015–2020 · strength 0.14
  25. Michael Bau Mortensen · 2 shared papers, 2016–2019 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.